1 May 2021 in Multiple Sclerosis and Related Disorders
MAMariana Agudelo-Arrieta
7 April 2022 in Therapeutic Apheresis and Dialysis
25 October 2025 in Multiple Sclerosis and Related Disorders
ACAndrés Felipe Cárdenas-Cruz
Andrés Felipe Cárdenas-Cruz
Chronic inflammation is a key driver of disability progression in multiple sclerosis (MS). Paramagnetic rim lesions (PRLs), which correspond to imaging markers of chronic active lesions (CALs), have emerged as candidate biomarkers of disease severity. Although associated with progression, the current evidence is limited by small sample sizes, short follow-up periods, and incomplete adjustment for confounding factors. To evaluate whether PRLs detected by susceptibility-weighted imaging (SWI), filtered phase, or quantitative susceptibility mapping (QSM) using 3T or 7T MRI predict progression independent of relapse activity (PIRA) or disability progression confirmed at 6 months (CDP), as measured by the Expanded Disability Status Scale (EDSS), in adults with MS. We systematically searched PubMed and Embase to identify studies evaluating associations between PRLs and disability progression in MS. Risk of bias was assessed with the Quality In Prognosis Studies (QUIPS) tool, and certainty of evidence was graded using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework. Five studies including 744 patients were analyzed. The presence of PRLs was associated with a higher risk of PIRA (odds ratio [OR] 2.24; 95 % confidence interval [CI]: 1.17-4.29; p = 0.01) and CDP (OR 2.87; 95 % CI: 1.01-8.1; p = 0.05). In studies with ≤4 years of follow-up, the association with PIRA was stronger (OR 2.84; 95 % CI: 1.72-4.68; p < 0.0001). Certainty of evidence was rated as moderate for PIRA and low for CDP. PRLs are associated with an increased risk of MS progression through PIRA. Clinical trials investigating novel disease-modifying therapies (DMTs) that target chronic inflammation and prevent disability progression should consider the presence of PRLs at baseline.
1 August 2013 in Biomédica
Costo-efectividad del tratamiento con interferón beta en pacientes con síndrome clínico aislado de alto riesgo en Colombia
2 September 2025 in Multiple Sclerosis and Related Disorders
Headache is a common but underrecognized symptom in optic neuritis (ON), with potential implications for diagnosis and management. To assess the clinical and radiological factors associated with headache in patients with acute ON. We conducted a retrospective case-control study in a tertiary hospital in Bogotá, Colombia (2022-2024). Adults diagnosed with ON based on clinical evaluation and magnetic resonance imaging (MRI) were included and classified according to the presence or absence of headache. Diagnosis was established based on the 2022 criteria proposed by Petzold et al. (1). MRI was reviewed by a neuroradiologist. Headache phenotypes were defined using ICHD-3 criteria. Logistic regression was used to identify independent predictors. Among 171 patients, 69 (40.4%) reported headache. Headache was associated with a personal history of primary headache (OR 7.14; 95% CI: 3.0-15.8; p = 0.009) and optic nerve lesions >12 mm (OR 2.34; 95% CI: 1.17-4.70; p = 0.016). Migraine without aura was the predominant phenotype (62.3%). Headache onset was simultaneous with vision loss in 58.0% of cases. No significant differences were found in antibody profiles or final diagnoses. Headache in ON is frequent, clinically relevant, and associated with radiological markers of inflammation. Systematic assessment of headache in ON may help identify patients with greater inflammatory burden, potentially guiding early diagnosis and individualized management.